COMPASS Pathways Plc American Depository Shares (CMPS) vs GH Research (GHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed GH Research (GHRS) over the past year, gaining 55.7% versus a gain of 25.1%. Over five years, GHRS leads with a -21.0% price change compared with -75.4% for CMPS. GH Research is the larger company by market cap ($1.20 billion vs $1.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | GHRS |
|---|---|---|
| Share price | $8.05 | $17.53 |
| Market cap | $1.14B | $1.20B |
| 1-day change | -6.94% | -5.55% |
| YTD return | +16.67% | +38.03% |
| 1-year return | +55.71% | +25.08% |
| 5-year return | -75.42% | -21.00% |
| EPS (TTM) | $-2.34 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-287.86M | $-48.26M |
| 52-week high | $15.87 | $31.44 |
| 52-week low | $4.88 | $12.04 |
| Distance from 52-week high | -49.28% | -44.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +189.57% | +144.67% |
| Average volume | 3.09M | 294.69K |
| Shares outstanding | 141.71M | 68.68M |
| Employees | 156 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed GHRS by 30.6 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
CMPS vs GHRS FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or GH Research?
GH Research (GHRS) is larger, with a market capitalization of $1.20B compared with $1.14B for COMPASS Pathways Plc American Depository Shares (CMPS).
Which stock has performed better over the past year, CMPS or GHRS?
CMPS returned +55.71% over the past 12 months, compared with +25.08% for GHRS (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and GH Research in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.